SeekingAlpha · Aug 24, 2026
The Bottom Fishing Club - Embecta: Excellent Turnaround Prospect In Defensive Medical Products
Embecta (EMBC) looks like a deep value buy: P/E under 3x, 50%+ FCF yield, insider buying and rebound setup.
OG
NYSE · OGN
Organon & Co.
Healthcare · Drug Manufacturers - General
$13.76
Up+$0.01 (+0.04%)
Updated Sep 1, 2026, 7:48 PM
SID Score
5.6/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.91B
- P/E ratio
- 3.82
- Dividend yield
- 2.47%
- 52-week range
- $5.69 – $13.77
- Volume
- 4.05M
- Avg. volume
- 5.64M
Price performance
OGN price history
1M range · 0 trading sessions · Daily adjusted prices
OGN does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest OGN news
The latest Smart Investors Daily articles mentioning OGN.
Stock researchCompany · Overview
OGN research
Overview
Company profile and research snapshot.
Company profile
Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $6.25
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Apr 29, 2026 | BNP Paribas | Neutral | — |
| Apr 28, 2026 | Piper Sandler | Neutral | — |
| Feb 24, 2026 | Barclays | Underweight | — |
| Dec 9, 2025 | Barclays | Underweight | — |
| Nov 11, 2025 | JP Morgan | Underweight | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 13, 2026
This House of Representative Just Sold Up To $30K In Organon Stock
A report on August 12, 2026 shows that Representative Kevin Hern from Oklahoma sale stock in Organon (NYSE:OGN), valued between $2,002 and $30,000. According to the August filing, the transaction occurred on August 5,
SeekingAlpha · Jul 31, 2026
Low Growth Viatris Is Due For A Pullback After A Stellar 16-Month Run
Viatris is rated a Sell due to persistent risks, weak financials, and a likely profit-taking event post-Q2 2026 earnings. Read more on VTRS stock here.
Benzinga · Jul 24, 2026
Organon To Present Results From Post Hoc Analysis Of Pooled Data From Phase 3 Pivotal Trials, ADORING 1 And ADORING 2, Evaluating VTAMA Cream Versus Vehicle At 2026 SPD Annual Meeting
The presentation at the 2026 Society for Pediatric Dermatology (SPD) Annual Meeting marked the first time pooled Phase 3 data from the ADORING 1 and 2 trials on Validated Investigator Global Assessment for Atopic
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
